Mereo BioPharma Group PLC ADR (MREO) — Cash Flow Quality Index

Latest as of December 2021: -24.07x

Mereo BioPharma Group PLC ADR (MREO) has a Cash Flow Quality Index of -24.07x as of December 2021. Operating cash flow of $-20.89 Million is below net income of $867.99K, suggesting accrual-heavy earnings not yet converted to cash. Explore Mereo BioPharma Group PLC ADR (MREO) cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

-24.07x

Operating CF / Net Income

Operating Cash Flow

$-20.89 Million

USD

Net Income

$867.99K

USD

Data as of

Dec 2021

Most recent filing

Mereo BioPharma Group PLC ADR Cash Flow Quality Index (2021–2021)

Historical Cash Flow Quality Index for Mereo BioPharma Group PLC ADR across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check MREO total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Mereo BioPharma Group PLC ADR (2021–2021)

Year-by-year earnings quality comparison for Mereo BioPharma Group PLC ADR. For live market cap and the full company financial profile, see Mereo BioPharma Group PLC ADR market cap and net worth.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change
2021	-0.37x	$-7.07 Million	$19.22 Million	—

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.